Presentation

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and
commercialize novel drugs that address unmet medical needs and have a clear development and
market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical
development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq
Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging
developed to improve the detection and visualization of focal liver lesions (including liver metastases
and primary tumors) in patients with reduced kidney function. These patients are at risk of serious
side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which
has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is
currently in Phase 3 development, including the global multi-center SPARKLE study.
l
Oncoral is a novel oral irinotecan chemotherapy tablet for the treatment of gastric cancer. Oncoral
has the potential to offer a more patient friendly cancer drug regimen including a better safety
profile following daily tablet dosing at home compared to intravenous high-dose infusions at the
hospital. Following successful Phase 1 results, the Phase 2 for Oncoral is in preparation.